Johnson & Johnson’s Covid-19 single-shot vaccine was shown to be 66% effective i…


Johnson & Johnson’s Covid-19 single-shot vaccine was shown to be 66% effective in preventing moderate and severe disease in a global Phase 3 trial, but 85% efficacy against severe disease, the company announced Friday. The vaccine was 72% effective against moderate and severe disease in the US, the company said. It’s a striking difference from vaccines from Pfizer/BioNTech and Moderna that have been shown to be about 95% effective against symptomatic disease. But experts say the Johnson & Johnson vaccine would be a useful tool that can reduce strain on health care systems and prevent hospitalization and death.⁠

(📸: Michael Ciaglo/Getty Images)⁠



Credit to the Original Source

(Visited 2 times, 1 visits today)

About The Author

You might be interested in

Comment (24)

  1. Remind me again how much Johnson & Johnson had to pay in compensation when they were sued because they knew they had cancer causing products and their baby powder and didn’t take it out for years? It was billions wasn’t it?
    I think I’ll be passing on this company.

  2. Nope. Johnson & Johnson knowingly gave cancer to thousands of people. They do not care about saving people. They care about money. Have a seat.

  3. They need to come up to at least 95% like the other 2 vaccines we already have going on for us.
    .
    .
    PS: I roast Karens on my page 👱🏻‍♀️

LEAVE YOUR COMMENT

Your email address will not be published. Required fields are marked *